Loading stock data…
INSP
$41.92-2.14 (-4.86%)
Pre-Market$41.92+0.00 (+0.00%)· Last close May 13
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inspire Medical Systems, Inc. in the Healthcare sector is trading at $41.92. Wall Street consensus targets $53.33 (12 analysts), implying a +27.2% move over the next 12 months. The stock is currently near its 52-week low of $41.55, remaining 47.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +27.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 18) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$41.92
Potential Upside
79.6%
Whystock Fair Value$75.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Hold
Mean target$53.33+27.2%
Range$45.00 – $65.00
Fundamentals
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.62B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.52
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.80%
Volume
Today's trading volume
924,878
Recent News
5 Insightful Analyst Questions From Inspire Medical Systems’s Q1 Earnings Call
Inspire Medical Systems’ first quarter results were met with a significant negative response from the market, as management pointed to persistent challenges in reimbursement coding and operational disruptions related to the WISER program. CEO Timothy Herbert described the period as one of uncertainty, highlighting that both the ongoing reimbursement confusion and new prior authorization requirements in six WISER pilot states materially impacted the company’s revenue pipeline. These factors led t
Things Look Grim For Inspire Medical Systems, Inc. (NYSE:INSP) After Today's Downgrade
The analysts covering Inspire Medical Systems, Inc. ( NYSE:INSP ) delivered a dose of negativity to shareholders today...
Inspire Medical Systems (INSP) Is Down 18.8% After Cutting 2026 Guidance Amid Reimbursement Challenges - What's Changed
In early May 2026, Inspire Medical Systems reported first-quarter 2026 results showing sales of US$204.58 million and a net loss of US$11.29 million, while also revising full-year 2026 revenue guidance down to US$825 million–US$875 million and diluted EPS to US$0.07–US$0.62 amid reimbursement and coding challenges. Shortly after, the company filed a US$118.82 million shelf registration for 2,600,000 common shares tied to its employee stock ownership plan and secured shareholder approval to...
Inspire Medical Q1 Earnings Beat Estimates, 2026 View Cut, Stock Down
INSP beats Q1 estimates but slashes 2026 outlook as reimbursement disruptions and WISeR program weigh on growth and procedure volumes.
Roblox downgraded, Chipotle upgraded: Wall Street's top analyst calls
Roblox downgraded, Chipotle upgraded: Wall Street's top analyst calls